UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

Geddes, J; Freemantle, N; Harrison, P; Bebbington, P; Natl Schizophrenia Guideline Dev; (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BRIT MED J , 321 (7273) 1371 - 1376. Green open access

[thumbnail of 1371.pdf]
Preview
PDF
1371.pdf

Download (293kB)

Abstract

Objective To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia.Design Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines.Subjects 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics.Main outcome measures Overall symptom scores. Rate of drop out las a proxy for tolerability) and of side effects, notably extrapyramidal side effects.Results For both symptom reduction and drop out, there was substantial heterogeneity between the results of trials, including those evaluating the same atypical antipsychotic and comparator drugs. Meta-regression suggested that dose of conventional antipsychotic explained the heterogeneity. When the dose was less than or equal to 12 mg/day of haloperidol (or equivalent), atypical antipsychotics had no benefits in terms of efficacy or overall tolerability, but they still caused fewer extrapyramidal side effects.Conclusions There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotics. Conventional antipsychotics should usually be used in the initial treatment of an episode of schizophrenia unless the patient has previously not responded to these drugs or has unacceptable extrapyramidal side effects.

Type: Article
Title: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
Open access status: An open access version is available from UCL Discovery
Keywords: RANDOMIZED CONTROLLED-TRIALS, TARDIVE-DYSKINESIA, METAANALYSIS, OLANZAPINE, RISPERIDONE, SCALE, CARE
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > IoN RLW Inst of Neurological Sci
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > Comprehensive CTU at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/2125
Downloads since deposit
2,284Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item